celecoxib has been researched along with Arthritis in 106 studies
Arthritis: Acute or chronic inflammation of JOINTS.
| Excerpt | Relevance | Reference |
|---|---|---|
| "For this industry-independent, double-blind, double-dummy, randomised trial done in one academic hospital in Hong Kong, we screened patients with arthritis and cardiothrombotic diseases who were presenting with upper gastrointestinal bleeding, were on NSAIDs, and require concomitant aspirin." | 9.24 | Gastrointestinal safety of celecoxib versus naproxen in patients with cardiothrombotic diseases and arthritis after upper gastrointestinal bleeding (CONCERN): an industry-independent, double-blind, double-dummy, randomised trial. ( Au, KWL; Chan, FKL; Chan, H; Cheong, PK; Ching, JYL; Kee, KM; Kyaw, MH; Lam, K; Lee, V; Lo, A; Ng, SC; Suen, BY; Tse, YK; Wong, GLH; Wong, VWS; Wu, JCY, 2017) |
| "Patients who required NSAIDs for osteoarthritis or rheumatoid arthritis and were at increased cardiovascular risk were randomly assigned to receive celecoxib, ibuprofen, or naproxen." | 9.22 | Cardiovascular Safety of Celecoxib, Naproxen, or Ibuprofen for Arthritis. ( Bao, W; Beckerman, B; Berger, MF; Borer, JS; Gaffney, M; Graham, DY; Husni, ME; Libby, P; Lincoff, AM; Lüscher, TF; Menon, V; Nissen, SE; Ruschitzka, F; Solomon, DH; Wang, Q; Wisniewski, LM; Wolski, KE; Yeomans, ND, 2016) |
| "To compare the safety and efficacy of celecoxib versus diclofenac slow release (SR) plus omeprazole in elderly arthritis patients." | 9.16 | Efficacy and safety of celecoxib versus diclofenac and omeprazole in elderly arthritis patients: a subgroup analysis of the CONDOR trial. ( Essex, MN; Kellner, HL; Li, C, 2012) |
| "In this double-blind, parallel-group, multicenter study, 537 patients with osteoarthritis (OA) or rheumatoid arthritis (RA) were randomized to treatment with celecoxib 200 mg b." | 9.09 | Reduced incidence of gastroduodenal ulcers with celecoxib, a novel cyclooxygenase-2 inhibitor, compared to naproxen in patients with arthritis. ( Burr, AM; Correa, P; Geis, GS; Goldstein, JL; Hubbard, RC; Verburg, KM; Zhao, WW, 2001) |
| "A 55-year-old woman who was treated for periarthritis humeroscapularis with celecoxib (Celebrex) developed a generalized pustular exanthema on the head and upper trunk, accompanied by fever, leukocytosis and increased erythrocyte sedimentation rate." | 8.82 | Acute generalized exanthematic pustulosis: a case and an overview of side effects affecting the skin caused by celecoxib and other COX-2 inhibitors reported so far. ( Braathen, LR; Goeschke, B, 2004) |
| " This paper summarizes the Arthritis Cost Consequence Evaluation System (ACCES)--a pharmacoeconomic model that has been developed to predict and evaluate the costs and consequences associated with the use of celecoxib in patients with arthritis, compared with other NSAIDs and NSAIDs plus gastroprotective agents." | 8.80 | Overview of the arthritis Cost Consequence Evaluation System (ACCES): a pharmacoeconomic model for celecoxib. ( Burke, T; Goldstein, JL; Maniadakis, N; McGuire, A; Pettitt, D; Schwartz, JS, 2000) |
| "The aim of this study is to clarify the following two points: First, whether a cyclooxygenase-2 mediated pathway is involved in the formation of immobilization-induced joint contracture and, second, the effectiveness of oral administration of non-steroidal anti-inflammatory drug celecoxib (CBX) for the prevention of myogenic and arthrogenic contracture following immobilization in a rat model." | 7.83 | Cyclooxygenase-2 inhibitor celecoxib attenuates joint contracture following immobilization in rat knees. ( Kaneguchi, A; Kito, N; Moriyama, H; Ozawa, J; Tanaka, R, 2016) |
| "PWD was significantly longer in inflammatory arthritis patients treated with celecoxib, compared to both healthy and inflammatory arthritis patients (P = 0." | 7.80 | Celecoxib-induced change in atrial electrophysiologic substrate in arthritis patients. ( Abdollah, H; Averns, HL; Baranchuk, A; Michael, KA; Pizzuto, K; Redfearn, DP; Simpson, C, 2014) |
| "To determine whether the cyclooxygenase-2 (COX-2) inhibitor celecoxib affects cardiovascular thrombotic risk, we analyzed the incidence of cardiovascular events for celecoxib, placebo, and nonsteroidal anti-inflammatory drugs (NSAIDs) in the entire controlled, arthritis clinical trial database for celecoxib." | 7.72 | Cardiovascular thrombotic events in arthritis trials of the cyclooxygenase-2 inhibitor celecoxib. ( Borer, JS; Faich, G; Makuch, RW; White, WB, 2003) |
| "Pain management in patients with osteoarthritis or rheumatoid arthritis often requires long-term use of nonsteroidal antiinflammatory drugs (NSAIDs)." | 6.74 | Rationale, design, and governance of Prospective Randomized Evaluation of Celecoxib Integrated Safety versus Ibuprofen Or Naproxen (PRECISION), a cardiovascular end point trial of nonsteroidal antiinflammatory agents in patients with arthritis. ( Becker, MC; Borer, JS; Graham, DY; Husni, ME; Krum, H; Libby, P; Lincoff, AM; Lüscher, TF; Mascette, AM; Nissen, SE; Ruschitzka, F; Solomon, DH; Wang, TH; Wisniewski, L; Wolski, K; Yeomans, ND, 2009) |
| "For this industry-independent, double-blind, double-dummy, randomised trial done in one academic hospital in Hong Kong, we screened patients with arthritis and cardiothrombotic diseases who were presenting with upper gastrointestinal bleeding, were on NSAIDs, and require concomitant aspirin." | 5.24 | Gastrointestinal safety of celecoxib versus naproxen in patients with cardiothrombotic diseases and arthritis after upper gastrointestinal bleeding (CONCERN): an industry-independent, double-blind, double-dummy, randomised trial. ( Au, KWL; Chan, FKL; Chan, H; Cheong, PK; Ching, JYL; Kee, KM; Kyaw, MH; Lam, K; Lee, V; Lo, A; Ng, SC; Suen, BY; Tse, YK; Wong, GLH; Wong, VWS; Wu, JCY, 2017) |
| "Patients who required NSAIDs for osteoarthritis or rheumatoid arthritis and were at increased cardiovascular risk were randomly assigned to receive celecoxib, ibuprofen, or naproxen." | 5.22 | Cardiovascular Safety of Celecoxib, Naproxen, or Ibuprofen for Arthritis. ( Bao, W; Beckerman, B; Berger, MF; Borer, JS; Gaffney, M; Graham, DY; Husni, ME; Libby, P; Lincoff, AM; Lüscher, TF; Menon, V; Nissen, SE; Ruschitzka, F; Solomon, DH; Wang, Q; Wisniewski, LM; Wolski, KE; Yeomans, ND, 2016) |
| "To compare the safety and efficacy of celecoxib versus diclofenac slow release (SR) plus omeprazole in elderly arthritis patients." | 5.16 | Efficacy and safety of celecoxib versus diclofenac and omeprazole in elderly arthritis patients: a subgroup analysis of the CONDOR trial. ( Essex, MN; Kellner, HL; Li, C, 2012) |
| "We performed a placebo-controlled pilot trial to evaluate the safety of celecoxib in patients with ulcerative colitis in remission who had a present or past history of nonspecific arthritis, arthralgia, or other condition amenable to nonsteroidal anti-inflammatory drug therapy." | 5.12 | Safety of celecoxib in patients with ulcerative colitis in remission: a randomized, placebo-controlled, pilot study. ( Bloom, BJ; Brynskov, J; Kent, JD; Lorenz, RG; Robbins, JL; Sandborn, WJ; Steidle, GM; Stenson, WF, 2006) |
| "In this double-blind, parallel-group, multicenter study, 537 patients with osteoarthritis (OA) or rheumatoid arthritis (RA) were randomized to treatment with celecoxib 200 mg b." | 5.09 | Reduced incidence of gastroduodenal ulcers with celecoxib, a novel cyclooxygenase-2 inhibitor, compared to naproxen in patients with arthritis. ( Burr, AM; Correa, P; Geis, GS; Goldstein, JL; Hubbard, RC; Verburg, KM; Zhao, WW, 2001) |
| "A 55-year-old woman who was treated for periarthritis humeroscapularis with celecoxib (Celebrex) developed a generalized pustular exanthema on the head and upper trunk, accompanied by fever, leukocytosis and increased erythrocyte sedimentation rate." | 4.82 | Acute generalized exanthematic pustulosis: a case and an overview of side effects affecting the skin caused by celecoxib and other COX-2 inhibitors reported so far. ( Braathen, LR; Goeschke, B, 2004) |
| " Preliminary data suggest that celecoxib, a highly selective COX-2 inhibitor, is superior to placebo and similar to traditional NSAIDs in the short-term treatment of pain due to osteoarthritis, although it has been associated with adverse effects such as headache, change in bowel habits, abdominal discomfort, and dizziness." | 4.80 | Selective cyclooxygenase-2 inhibitors for the treatment of arthritis. ( Fung, HB; Kirschenbaum, HL, 1999) |
| " This paper summarizes the Arthritis Cost Consequence Evaluation System (ACCES)--a pharmacoeconomic model that has been developed to predict and evaluate the costs and consequences associated with the use of celecoxib in patients with arthritis, compared with other NSAIDs and NSAIDs plus gastroprotective agents." | 4.80 | Overview of the arthritis Cost Consequence Evaluation System (ACCES): a pharmacoeconomic model for celecoxib. ( Burke, T; Goldstein, JL; Maniadakis, N; McGuire, A; Pettitt, D; Schwartz, JS, 2000) |
| "The aim of this study is to clarify the following two points: First, whether a cyclooxygenase-2 mediated pathway is involved in the formation of immobilization-induced joint contracture and, second, the effectiveness of oral administration of non-steroidal anti-inflammatory drug celecoxib (CBX) for the prevention of myogenic and arthrogenic contracture following immobilization in a rat model." | 3.83 | Cyclooxygenase-2 inhibitor celecoxib attenuates joint contracture following immobilization in rat knees. ( Kaneguchi, A; Kito, N; Moriyama, H; Ozawa, J; Tanaka, R, 2016) |
| "PWD was significantly longer in inflammatory arthritis patients treated with celecoxib, compared to both healthy and inflammatory arthritis patients (P = 0." | 3.80 | Celecoxib-induced change in atrial electrophysiologic substrate in arthritis patients. ( Abdollah, H; Averns, HL; Baranchuk, A; Michael, KA; Pizzuto, K; Redfearn, DP; Simpson, C, 2014) |
| " In a cohort study comparing the risk of upper gastrointestinal complications in celecoxib or traditional NSAIDs (diclofenac, ibuprofen) initiators with rheumatoid arthritis and osteoarthritis, we (1) aggregated medications and International Classification of Diseases-9 (ICD-9) diagnoses into hierarchies of the Anatomical Therapeutic Chemical classification (ATC) and the Clinical Classification Software (CCS), respectively, and (2) sampled the full cohort using techniques validated by simulations to create 9,600 samples to compare 16 aggregation scenarios across 50% and 20% samples with varying outcome incidence and exposure prevalence." | 3.79 | Effects of aggregation of drug and diagnostic codes on the performance of the high-dimensional propensity score algorithm: an empirical example. ( Beach, KJ; Brookhart, MA; Layton, JB; Le, HV; Poole, C; Schoenbach, VJ; Stürmer, T, 2013) |
| "The determination of two sulphur-containing drugs, the COX-2 inhibitors celecoxib and etoricoxib, in the serum and synovial fluid of inflammatory arthritis patients, is described using a sensitive ultra performance liquid chromatography-inductively coupled plasma mass spectroscopy (UPLC/ICPMS) method." | 3.75 | Determination of two COX-2 inhibitors in serum and synovial fluid of patients with inflammatory arthritis by ultra performance liquid chromatography-inductively coupled plasma mass spectroscopy and quadrupole time-of-flight mass spectrometry. ( Diza, E; Gika, HG; Michopoulos, F; Nikolaidis, P; Settas, L; Smith, C; Theodoridis, G; Theodoridou, A; Wilson, ID, 2009) |
| "To estimate the net cardiovascular (CV) (coronary heart disease, stroke, congestive heart failure), and gastrointestinal (GI) (peptic ulcer complications) risk-benefit public health impact of the use of celecoxib compared to non-selective NSAIDs in the arthritis population." | 3.74 | Quantitative assessment of the gastrointestinal and cardiovascular risk-benefit of celecoxib compared to individual NSAIDs at the population level. ( Castellsague, J; Maguire, A; Perez-Gutthann, S; Varas-Lorenzo, C, 2007) |
| "This literature-based economic analysis (with data summarized from MEDLINE-indexed and other published sources, FDA reports, and data on file at VA San Diego Healthcare System) compared rofecoxib and celecoxib to NSAIDS in two arthritis patient populations considered at higher risk of developing clinically significant upper gastrointestinal events (CSUGIEs): (1) patients of any age with previous medical history of perforation/ulcer/bleed (PUB); and (2) patients 65 years and older (regardless of history of PUB)." | 3.73 | Assessing the cost-effectiveness of COX-2 specific inhibitors for arthritis in the Veterans Health Administration. ( Botteman, M; DeLattre, M; Gao, X; Morreale, A; Schaefer, M; Stephens, J, 2005) |
| "To determine whether the cyclooxygenase-2 (COX-2) inhibitor celecoxib affects cardiovascular thrombotic risk, we analyzed the incidence of cardiovascular events for celecoxib, placebo, and nonsteroidal anti-inflammatory drugs (NSAIDs) in the entire controlled, arthritis clinical trial database for celecoxib." | 3.72 | Cardiovascular thrombotic events in arthritis trials of the cyclooxygenase-2 inhibitor celecoxib. ( Borer, JS; Faich, G; Makuch, RW; White, WB, 2003) |
| " The first involves the case of the arthritis drug celecoxib (Celebrex), where the study lasted 12 months but the authors only presented 6 months of data." | 3.72 | Multiple comparisons in drug efficacy studies: scientific or marketing principles? ( Leo, J, 2004) |
| "Celecoxib, a specific inhibitor of cyclooxygenase-2, is used to treat the symptoms of arthritis." | 3.71 | Visual disturbance associated with celecoxib. ( Lund, BC; Neiman, RF, 2001) |
| "Celecoxib is predicted to be the most cost effective of the treatments considered for managing arthritis patients in Switzerland." | 3.71 | Economic evaluation of celecoxib, a new cyclo-oxygenase 2 specific inhibitor, in Switzerland. ( Chancellor, JV; de Cruz, E; Hunsche, E; Sarasin, FP, 2001) |
| " Our patient had arthritis of the hips and chronic atrial fibrillation and was on warfarin therapy for stroke prevention; less than a week after starting celecoxib therapy, gastrointestinal bleeding and hypoprothrombinemia occurred." | 3.70 | Cyclooxygenase-2 inhibitor celecoxib: a possible cause of gastropathy and hypoprothrombinemia. ( Davis, JV; Linder, JD; Mönkemüller, KE; Wilcox, CM, 2000) |
| "Pain management in patients with osteoarthritis or rheumatoid arthritis often requires long-term use of nonsteroidal antiinflammatory drugs (NSAIDs)." | 2.74 | Rationale, design, and governance of Prospective Randomized Evaluation of Celecoxib Integrated Safety versus Ibuprofen Or Naproxen (PRECISION), a cardiovascular end point trial of nonsteroidal antiinflammatory agents in patients with arthritis. ( Becker, MC; Borer, JS; Graham, DY; Husni, ME; Krum, H; Libby, P; Lincoff, AM; Lüscher, TF; Mascette, AM; Nissen, SE; Ruschitzka, F; Solomon, DH; Wang, TH; Wisniewski, L; Wolski, K; Yeomans, ND, 2009) |
| " However, clinical data suggest that chronic use of celecoxib, may impair normal skeletal function leading to decreased bone mineral density in older male patients." | 2.44 | Celecoxib, NSAIDs and the skeleton. ( Lysz, T; O'Connor, JP, 2008) |
| "Celecoxib is an effective anti-inflammatory, analgesic and antipyretic agent therapeutically utilised in the management of osteoarthritis and rheumatoid arthritis." | 2.41 | Celecoxib: a new option in the treatment of arthropathies and familial adenomatous polyposis. ( Davies, NM; de Leeuw, MA; Gudde, TW, 2001) |
| "We tested whether this parameter and tactile allodynia, the standard pain measure in preclinical studies, show parallels in their response to analgesics and basic mechanisms." | 1.46 | Grip strength in mice with joint inflammation: A rheumatology function test sensitive to pain and analgesia. ( Cañizares, FJ; Cobos, EJ; Entrena, JM; Fernández-Segura, E; Montilla-García, Á; Perazzoli, G; Portillo-Salido, E; Tejada, MÁ, 2017) |
| "We report a three-fold increase in lung metastasis and a significant increase in the incidence of bone metastasis in the pro-arthritic and arthritic mice compared to non-arthritic control mice." | 1.35 | Breast-cancer-associated metastasis is significantly increased in a model of autoimmune arthritis. ( Das Roy, L; Gruber, HE; Mukherjee, P; Pathangey, LB; Schettini, JL; Tinder, TL, 2009) |
| "Swelling and mechanical and thermal hyperalgesia were assessed before and for 28 days after the onset of arthritis." | 1.34 | Collagen-induced arthritis as a model of hyperalgesia: functional and cellular analysis of the analgesic actions of tumor necrosis factor blockade. ( Anand, P; Essex, D; Feldmann, M; Inglis, JJ; Notley, CA; Williams, R; Wilson, AW, 2007) |
| " The factors that predispose to adverse events by NSAIDs are unknown." | 1.33 | Nitric oxide deficiency promotes vascular side effects of cyclooxygenase inhibitors. ( Anning, PB; Coles, B; Dey, SK; Marnett, LJ; Morrow, JD; Morton, J; O'Donnell, VB; Uddin, J; Wang, H, 2006) |
| "Celecoxib users were 4." | 1.32 | Persistence with COX-2 inhibitors in managed care: an analysis of claims data. ( Harley, C; Wagner, S, 2003) |
| "Electrolyte disorders and acute renal failure are observed more frequently in patients with risk factors." | 1.31 | [Renal tolerance of selective inhibitors of cyclooxygenase type 2]. ( Deray, G, 2001) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 11 (10.38) | 18.2507 |
| 2000's | 74 (69.81) | 29.6817 |
| 2010's | 20 (18.87) | 24.3611 |
| 2020's | 1 (0.94) | 2.80 |
| Authors | Studies |
|---|---|
| Inagaki, M | 1 |
| Tsuri, T | 1 |
| Jyoyama, H | 1 |
| Ono, T | 1 |
| Yamada, K | 1 |
| Kobayashi, M | 1 |
| Hori, Y | 1 |
| Arimura, A | 1 |
| Yasui, K | 1 |
| Ohno, K | 1 |
| Kakudo, S | 1 |
| Koizumi, K | 1 |
| Suzuki, R | 1 |
| Kawai, S | 1 |
| Kato, M | 1 |
| Matsumoto, S | 1 |
| da Silva, YK | 1 |
| Augusto, CV | 1 |
| de Castro Barbosa, ML | 1 |
| de Albuquerque Melo, GM | 1 |
| de Queiroz, AC | 1 |
| de Lima Matos Freire Dias, T | 1 |
| Júnior, WB | 1 |
| Barreiro, EJ | 1 |
| Lima, LM | 1 |
| Alexandre-Moreira, MS | 1 |
| Komaki, R | 1 |
| Miyagaki, T | 1 |
| Nakajima, K | 1 |
| Mitsuishi, S | 1 |
| Kishi, A | 1 |
| Miyano, K | 1 |
| Okano, T | 1 |
| Takeuchi, S | 1 |
| Suzuki, S | 1 |
| Kadono, T | 1 |
| Grosser, T | 1 |
| Nissen, SE | 3 |
| Chan, FKL | 1 |
| Ching, JYL | 1 |
| Tse, YK | 1 |
| Lam, K | 1 |
| Wong, GLH | 1 |
| Ng, SC | 1 |
| Lee, V | 1 |
| Au, KWL | 1 |
| Cheong, PK | 1 |
| Suen, BY | 3 |
| Chan, H | 1 |
| Kee, KM | 1 |
| Lo, A | 1 |
| Wong, VWS | 1 |
| Wu, JCY | 1 |
| Kyaw, MH | 1 |
| Onuora, S | 1 |
| Antman, EM | 1 |
| Montilla-García, Á | 1 |
| Tejada, MÁ | 1 |
| Perazzoli, G | 1 |
| Entrena, JM | 1 |
| Portillo-Salido, E | 1 |
| Fernández-Segura, E | 1 |
| Cañizares, FJ | 1 |
| Cobos, EJ | 1 |
| Chan, N | 1 |
| Weitz, J | 1 |
| Weintraub, WS | 1 |
| Laine, L | 1 |
| Yeomans, ND | 3 |
| Graham, DY | 4 |
| Le, HV | 1 |
| Poole, C | 1 |
| Brookhart, MA | 1 |
| Schoenbach, VJ | 1 |
| Beach, KJ | 1 |
| Layton, JB | 1 |
| Stürmer, T | 1 |
| Pizzuto, K | 1 |
| Averns, HL | 1 |
| Baranchuk, A | 1 |
| Abdollah, H | 1 |
| Michael, KA | 1 |
| Simpson, C | 1 |
| Redfearn, DP | 1 |
| Ozawa, J | 1 |
| Kaneguchi, A | 1 |
| Tanaka, R | 1 |
| Kito, N | 1 |
| Moriyama, H | 1 |
| Solomon, DH | 2 |
| Lüscher, TF | 2 |
| Libby, P | 2 |
| Husni, ME | 2 |
| Borer, JS | 3 |
| Wisniewski, LM | 1 |
| Wolski, KE | 1 |
| Wang, Q | 1 |
| Menon, V | 1 |
| Ruschitzka, F | 2 |
| Gaffney, M | 1 |
| Beckerman, B | 1 |
| Berger, MF | 1 |
| Bao, W | 1 |
| Lincoff, AM | 2 |
| González-Gay, MA | 1 |
| González-Juanatey, C | 1 |
| Lee, JH | 1 |
| Park, HK | 1 |
| Heo, J | 1 |
| Kim, TO | 1 |
| Kim, GH | 1 |
| Kang, DH | 1 |
| Song, GA | 1 |
| Cho, M | 1 |
| Kim, DS | 1 |
| Kim, HW | 1 |
| Lee, CH | 1 |
| Gradilone, A | 1 |
| Spadaro, A | 1 |
| Gianni, W | 1 |
| Aglianò, AM | 1 |
| Gazzaniga, P | 1 |
| O'Connor, JP | 1 |
| Lysz, T | 1 |
| Gika, HG | 1 |
| Theodoridou, A | 1 |
| Michopoulos, F | 1 |
| Theodoridis, G | 1 |
| Diza, E | 1 |
| Settas, L | 1 |
| Nikolaidis, P | 1 |
| Smith, C | 1 |
| Wilson, ID | 1 |
| Becker, MC | 1 |
| Wang, TH | 1 |
| Wisniewski, L | 1 |
| Wolski, K | 1 |
| Mascette, AM | 1 |
| Krum, H | 1 |
| Park, DS | 1 |
| Huh, JE | 1 |
| Baek, YH | 1 |
| Das Roy, L | 1 |
| Pathangey, LB | 1 |
| Tinder, TL | 1 |
| Schettini, JL | 1 |
| Gruber, HE | 1 |
| Mukherjee, P | 1 |
| Ross, E | 1 |
| Morito, H | 1 |
| Ogawa, K | 1 |
| Kobayashi, N | 1 |
| Fukumoto, T | 1 |
| Asada, H | 1 |
| Blackler, R | 1 |
| Syer, S | 1 |
| Bolla, M | 1 |
| Ongini, E | 1 |
| Wallace, JL | 1 |
| Kellner, HL | 1 |
| Li, C | 1 |
| Essex, MN | 1 |
| Alper, AB | 1 |
| Meleg-Smith, S | 1 |
| Krane, NK | 1 |
| Håkansson, J | 1 |
| Chan, FK | 3 |
| Hung, LC | 2 |
| Wu, JC | 2 |
| Lee, KC | 1 |
| Leung, VK | 1 |
| Hui, AJ | 2 |
| To, KF | 2 |
| Leung, WK | 2 |
| Wong, VW | 2 |
| Chung, SC | 2 |
| Sung, JJ | 2 |
| Gibofsky, A | 1 |
| Bandyopadhyay, D | 1 |
| White, WB | 1 |
| Faich, G | 1 |
| Makuch, RW | 1 |
| Kerr, SJ | 1 |
| Mant, A | 1 |
| Horn, FE | 1 |
| McGeechan, K | 1 |
| Sayer, GP | 1 |
| Harley, C | 1 |
| Wagner, S | 1 |
| Wright, JM | 1 |
| Olin, JL | 1 |
| Chan, A | 1 |
| Lazarus, DS | 1 |
| Goeschke, B | 1 |
| Braathen, LR | 1 |
| Lee, YT | 1 |
| Cryer, B | 1 |
| Vanchieri, C | 1 |
| Topol, EJ | 1 |
| Leo, J | 1 |
| Okie, S | 1 |
| Spiegel, BM | 1 |
| Chiou, CF | 1 |
| Ofman, JJ | 1 |
| Schaefer, M | 1 |
| DeLattre, M | 1 |
| Gao, X | 1 |
| Stephens, J | 1 |
| Botteman, M | 1 |
| Morreale, A | 1 |
| Clifford, TM | 1 |
| Pajoumand, M | 1 |
| Johnston, TD | 1 |
| Olsen, NJ | 1 |
| Krüger, K | 1 |
| Pamuk, ON | 1 |
| Cakir, N | 1 |
| Allen, MJ | 1 |
| McLean-Veysey, P | 1 |
| Fleming, I | 1 |
| Sandborn, WJ | 1 |
| Stenson, WF | 1 |
| Brynskov, J | 1 |
| Lorenz, RG | 1 |
| Steidle, GM | 1 |
| Robbins, JL | 1 |
| Kent, JD | 1 |
| Bloom, BJ | 1 |
| Varas-Lorenzo, C | 1 |
| Maguire, A | 1 |
| Castellsague, J | 1 |
| Perez-Gutthann, S | 1 |
| Anning, PB | 1 |
| Coles, B | 1 |
| Morton, J | 1 |
| Wang, H | 1 |
| Uddin, J | 1 |
| Morrow, JD | 1 |
| Dey, SK | 1 |
| Marnett, LJ | 1 |
| O'Donnell, VB | 1 |
| Mukherjee, D | 1 |
| Heim, HK | 1 |
| Broich, K | 1 |
| Tabrizchi, R | 1 |
| Frampton, JE | 1 |
| Keating, GM | 1 |
| Inglis, JJ | 1 |
| Notley, CA | 1 |
| Essex, D | 1 |
| Wilson, AW | 1 |
| Feldmann, M | 1 |
| Anand, P | 1 |
| Williams, R | 1 |
| Peura, D | 1 |
| Wilcox, CM | 2 |
| Niculescu, L | 1 |
| Berger, M | 1 |
| Ziegler, J | 1 |
| Miller, JL | 1 |
| Nightingale, SL | 1 |
| Marshall, KW | 1 |
| Trippel, SB | 1 |
| Lipsky, PE | 1 |
| Fort, J | 1 |
| Brink, S | 1 |
| Lefkowith, JB | 1 |
| Karch, AM | 1 |
| Karch, FE | 1 |
| Fung, HB | 1 |
| Kirschenbaum, HL | 1 |
| Smigel, K | 1 |
| McMorran, M | 1 |
| Morawiecka, I | 1 |
| Noble, SL | 1 |
| King, DS | 1 |
| Olutade, JI | 1 |
| Urban, MK | 1 |
| Linder, JD | 1 |
| Mönkemüller, KE | 1 |
| Davis, JV | 1 |
| Kremer, J | 1 |
| Everts, B | 1 |
| Währborg, P | 1 |
| Hedner, T | 1 |
| Lund, BC | 1 |
| Neiman, RF | 1 |
| Pettitt, D | 2 |
| Goldstein, JL | 3 |
| McGuire, A | 1 |
| Schwartz, JS | 1 |
| Burke, T | 1 |
| Maniadakis, N | 2 |
| Burke, TA | 1 |
| Zabinski, RA | 1 |
| Maurath, CJ | 1 |
| Chancellor, JV | 1 |
| Hunsche, E | 1 |
| de Cruz, E | 1 |
| Sarasin, FP | 1 |
| Correa, P | 1 |
| Zhao, WW | 1 |
| Burr, AM | 1 |
| Hubbard, RC | 1 |
| Verburg, KM | 1 |
| Geis, GS | 1 |
| Davies, NM | 1 |
| Gudde, TW | 1 |
| de Leeuw, MA | 1 |
| FitzGerald, GA | 2 |
| Patrono, C | 1 |
| Comarow, A | 1 |
| Peretz, A | 1 |
| Deray, G | 1 |
| Simon, LS | 1 |
| McColl, GJ | 1 |
| Fux, R | 1 |
| Mörike, K | 1 |
| Gleiter, CH | 1 |
| Hawkey, CJ | 1 |
| Crofford, LJ | 1 |
| Jüni, P | 1 |
| Rutjes, AW | 1 |
| Dieppe, PA | 1 |
| Rego, MJ | 1 |
| Fonseré, N | 1 |
| Martí, S | 1 |
| Rey-Joly, C | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Double-blind Randomized Comparison of Celecoxib Plus Esomeprazole Versus Naproxen Plus Esomeprazole for Prevention of Recurrent Ulcer Bleeding in Patients With Arthritis and Cardiothrombotic Diseases (NSAID#8 Study)[NCT00153660] | Phase 3 | 514 participants (Actual) | Interventional | 2005-06-30 | Completed | ||
| A Randomized, Double Blind, Parallel-group Study Of Cardiovascular Safety In Osteoarthritis Or Rheumatoid Arthritis Patients With Or At High Risk For Cardiovascular Disease Comparing Celecoxib With Naproxen And Ibuprofen[NCT00346216] | Phase 4 | 24,081 participants (Actual) | Interventional | 2006-10-04 | Completed | ||
| Single Dose Oral Celecoxib (With or Without Acetaminophen) for Acute Post-operative Pain Following Impacted Third Molar Surgery.[NCT04790812] | Phase 4 | 100 participants (Anticipated) | Interventional | 2021-04-22 | Recruiting | ||
| Use of a Self-Guided Mindfulness Mobile Application to Improve Pain Outcomes in Individuals With Knee Osteoarthritis[NCT03936088] | 75 participants (Actual) | Interventional | 2019-05-02 | Completed | |||
| Pain Modulation in RA - Influence of Adalimumab. A Randomized, Placebo-controlled Study Using Functional Magnetic Resonance Imaging (PARADE)[NCT01197144] | 70 participants (Actual) | Interventional | 2010-10-31 | Completed | |||
| A Placebo-Controlled, Double-Blind, Randomized Study of the Potential Interaction Between Aspirin and Ibuprofen or Celecoxib.[NCT00565500] | Phase 4 | 24 participants (Actual) | Interventional | 2003-04-30 | Completed | ||
| Clinical Phase II Pilot Study of the Efficacy of FANG(30) to Treat Active Rheumatoid Arthritis in Adult Patients[NCT00749645] | Phase 2 | 60 participants (Actual) | Interventional | 2006-10-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
"VAS question How much pain do you have was graded on a scale from 0 to 100 with 0 indicating No pain and 100 indicating Worst possible pain." (NCT00346216)
Timeframe: ITT and MITT Population - Baseline to 42 months
| Intervention | Number of participants (Mean) | |||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Baseline (ITT) N= 8014, 8001, 7928 | Change-Baseline to Mon1 (ITT) N=7382, 7379, 7325 | Change-Baseline to Mon2 (ITT) N=7180, 7090, 7149 | Change-Baseline to Mon4 (ITT) N=6777, 6696, 6740 | Change-Baseline to Mon8 (ITT) N=6230, 6137, 6159 | Change-Baseline to Mon12 (ITT) N=5792, 5696, 5846 | Change-Baseline to Mon18 (ITT) N=5310, 5181. 5246 | Change-Baseline to Mon24 (ITT) N=4818, 4776, 4785 | Change-Baseline to Mon30 (ITT) N=4140, 4069, 4086 | Change-Baseline to Mon36 (ITT) N=3692, 3627, 3635 | Change-Baseline to Mon42 (ITT) N=3469, 3406, 3439 | Baseline (MITT) N=7974, 7954, 7894 | Change-Baseline to Mon1 MITT N=7372, 7367, 7321 | Change-Baseline to Mon2 MITT N=7170, 7078, 7142 | Change-Baseline to Mon4 MITT N=6772, 6686, 6732 | Change-Baseline to Mon8 MITT N=6224, 6128, 6155 | Change-Baseline to Mon12 MITT N=5787, 5689, 5844 | Change-Baseline to Mon18 MITT N=5305, 5175, 5242 | Change-Baseline to Mon24 MITT N=4815, 4769, 4782 | Change-Baseline to Mon30 MITT N=4139, 4067, 4085 | Change-Baseline to Mon36 MITT N=3691, 3623, 3635 | Change-Baseline to Mon42 MITT N=3468, 3404, 3438 | |
| Celecoxib | 54.0 | -8.2 | -10.5 | -11.4 | -11.7 | -11.0 | -11.3 | -11.3 | -10.5 | -10.1 | -11.4 | 54.0 | -8.2 | -10.5 | -11.4 | -11.7 | -11.0 | -11.3 | -11.4 | -10.5 | -10.2 | -11.4 |
| Ibuprofen | 54.1 | -9.0 | -10.6 | -11.7 | -12.1 | -11.6 | -11.3 | -11.5 | -11.2 | -10.7 | -11.1 | 54.1 | -9.0 | -10.6 | -11.7 | -12.1 | -11.6 | -11.3 | -11.5 | -11.2 | -10.7 | -11.1 |
| Naproxen | 54.1 | -9.9 | -11.1 | -12.3 | -12.1 | -11.9 | -11.7 | -11.4 | -11.3 | -11.6 | -12.1 | 54.1 | -9.9 | -11.1 | -12.3 | -12.1 | -11.9 | -11.7 | -11.3 | -11.3 | -11.6 | -12.1 |
MACE defined as the composite of CV death (including hemorrhagic death), non-fatal MI, non-fatal stroke, hospitalization for UA, revascularization or hospitalization for TIA (NCT00346216)
Timeframe: ITT Population - 30 months; MITT Population - 42 months
| Intervention | Percentage of Participants (Number) | |
|---|---|---|
| ITT (N = 8072, 8040, 7969) | MITT (N = 8030, 7990, 7933) | |
| Celecoxib | 4.2 | 3.1 |
| Ibuprofen | 4.8 | 3.6 |
| Naproxen | 4.3 | 3.2 |
APTC events are defined as a composite of any of the following events: Death due to CV causes (including cardiac, cerebrovascular, venous thromboembolic, haemorrhagic, other vascular, or unknown cause); Non-fatal MI; Non-fatal stroke (including intracranial hemorrhages, stroke of ischemic or unknown etiology). (NCT00346216)
Timeframe: Intent to Treat (ITT) Population - 30 months; Modified ITT (MITT) Population - 42 months
| Intervention | Percentage of Partcipants (Number) | |
|---|---|---|
| ITT (N = 8072, 8040, 7969) | MITT (N = 8030, 7990, 7933) | |
| Celecoxib | 2.3 | 1.7 |
| Ibuprofen | 2.7 | 1.9 |
| Naproxen | 2.5 | 1.8 |
CSGIE include: Gastroduodenal (GD) hemorrhage, Gastric outlet obstruction, Gastroduodenal, small bowel or large bowel perforation, Large bowel hemorrhage, Small bowel hemorrhage, Acute GI hemorrhage of unknown origin, including presumed small bowel hemorrhage, Symptomatic gastric or duodenal ulcer (NCT00346216)
Timeframe: ITT Population - 30 months; MITT Population - 42 months
| Intervention | Percentage of Participants (Number) | |
|---|---|---|
| ITT (N = 8072, 8040, 7969) | MITT (N = 8030, 7990, 7933) | |
| Celecoxib | 0.7 | 0.3 |
| Ibuprofen | 0.9 | 0.7 |
| Naproxen | 0.7 | 0.7 |
28 reviews available for celecoxib and Arthritis
| Article | Year |
|---|---|
Evaluating the Cardiovascular Safety of Nonsteroidal Anti-Inflammatory Drugs.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis; Cardiotoxicity; Cardiovascular Diseases; Celecox | 2017 |
Celecoxib safety revisited.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Arthritis; Cardiovascular Diseases; Celecoxib; Cli | 2016 |
Celecoxib, NSAIDs and the skeleton.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Arthritis; Bone and Bones; Bone Regeneration; Cele | 2008 |
Update on the management of pain in arthritis and the use of cyclooxygenase-2 inhibitors.
Topics: Arthritis; Celecoxib; Cyclooxygenase 2 Inhibitors; Humans; Pain; Pyrazoles; Sulfonamides | 2009 |
Clinical profiles of celecoxib and rofecoxib in the rheumatic diseases.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis; Celecoxib; Cyclooxygenase Inhibitors; Humans; La | 2002 |
Acute generalized exanthematic pustulosis: a case and an overview of side effects affecting the skin caused by celecoxib and other COX-2 inhibitors reported so far.
Topics: Arm; Arthritis; Celecoxib; Cyclooxygenase Inhibitors; Diagnosis, Differential; Drug Eruptions; Exant | 2004 |
Minimizing complications from nonsteroidal antiinflammatory drugs: cost-effectiveness of competing strategies in varying risk groups.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Inflammatory Agents, Non-Steroidal; Arthritis; Aspirin | 2005 |
[The efficacy of selective Cox-2-inhibitors in comparison with conventional NSAIDs].
Topics: Acute Disease; Anti-Inflammatory Agents, Non-Steroidal; Antirheumatic Agents; Arthritis; Arthritis, | 2005 |
Does a coxib-associated thrombotic risk limit the clinical use of the compounds as analgesic anti-inflammatory drugs? Arguments in favor.
Topics: Analgesics; Animals; Anti-Inflammatory Agents, Non-Steroidal; Arthritis; Celecoxib; Cyclooxygenase 2 | 2006 |
Celecoxib: a review of its use in the management of arthritis and acute pain.
Topics: Acute Disease; Arthritis; Celecoxib; Cyclooxygenase 2 Inhibitors; Humans; Pain; Pyrazoles; Sulfonami | 2007 |
Cyclooxygenase-2 specificity and its clinical implications.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis; Arthritis, Rheumatoid; Celecoxib; Clinical Trial | 1999 |
Selective cyclooxygenase-2 inhibitors for the treatment of arthritis.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis; Celecoxib; Clinical Trials as Topic; Cyclooxygen | 1999 |
Cyclooxygenase-2 enzyme inhibitors: place in therapy.
Topics: Analgesics, Non-Narcotic; Anti-Inflammatory Agents, Non-Steroidal; Arthritis; Bleeding Time; Blood P | 2000 |
COX-2 specific inhibitors offer improved advantages over traditional NSAIDs.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis; Celecoxib; Cyclooxygenase 1; Cyclooxygenase 2; C | 2000 |
From prostaglandin replacement to specific COX-2 inhibition: a critical appraisal.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Agents; Arthritis; Celecoxib; Cyclooxygenase 2; | 2000 |
COX-2-Specific inhibitors--the emergence of a new class of analgesic and anti-inflammatory drugs.
Topics: Analgesics; Animals; Anti-Inflammatory Agents, Non-Steroidal; Arthritis; Celecoxib; Cyclooxygenase 2 | 2000 |
Are rofecoxib and celecoxib safer NSAIDS?
Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis; Celecoxib; Cyclooxygenase Inhibitors; Humans; La | 2000 |
Overview of the arthritis Cost Consequence Evaluation System (ACCES): a pharmacoeconomic model for celecoxib.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Arthritis; Celecoxib; Cost of Illness; Cost-Benefit A | 2000 |
A framework for evaluating the clinical consequences of initial therapy with NSAIDs, NSAIDs plus gastroprotective agents, or celecoxib in the treatment of arthritis.
Topics: Anemia; Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Agents; Arthritis; Celecoxib; Clinical T | 2001 |
Celecoxib: a new option in the treatment of arthropathies and familial adenomatous polyposis.
Topics: Absorption; Adenomatous Polyposis Coli; Animals; Arthritis; Celecoxib; Costs and Cost Analysis; Cycl | 2001 |
The coxibs, selective inhibitors of cyclooxygenase-2.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis; Cardiovascular Diseases; Celecoxib; Cyclooxygena | 2001 |
The coxibs, selective inhibitors of cyclooxygenase-2.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis; Cardiovascular Diseases; Celecoxib; Cyclooxygena | 2001 |
The coxibs, selective inhibitors of cyclooxygenase-2.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis; Cardiovascular Diseases; Celecoxib; Cyclooxygena | 2001 |
The coxibs, selective inhibitors of cyclooxygenase-2.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis; Cardiovascular Diseases; Celecoxib; Cyclooxygena | 2001 |
[COX-2 inhibitor non-steroidal anti-inflammatory drugs, myth or reality?].
Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis; Belgium; Celecoxib; Cyclooxygenase 2; Cyclooxyge | 2001 |
Arthritis. Should you be taking a COX-2 inhibitor?
Topics: Advertising; Anti-Inflammatory Agents, Non-Steroidal; Arthritis; Celecoxib; Cyclooxygenase 1; Cycloo | 2001 |
COX-2 inhibitors. Are they nonsteroidal anti-inflammatory drugs with a better safety profile?
Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis; Celecoxib; Cyclooxygenase 2; Cyclooxygenase 2 In | 2001 |
Pharmacological therapies for the treatment of osteoarthritis.
Topics: Acetaminophen; Analgesics, Non-Narcotic; Anti-Inflammatory Agents, Non-Steroidal; Arthritis; Celecox | 2001 |
[Celecoxib].
Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis; Cardiovascular System; Celecoxib; Contraindicati | 2002 |
Cyclooxygenase inhibition: between the devil and the deep blue sea.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis; Celecoxib; Cyclooxygenase 2; Cyclooxygenase 2 In | 2002 |
Specific cyclooxygenase-2 inhibitors: what have we learned since they came into widespread clinical use?
Topics: Arthritis; Aspirin; Cardiovascular System; Celecoxib; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; | 2002 |
9 trials available for celecoxib and Arthritis
| Article | Year |
|---|---|
Gastrointestinal safety of celecoxib versus naproxen in patients with cardiothrombotic diseases and arthritis after upper gastrointestinal bleeding (CONCERN): an industry-independent, double-blind, double-dummy, randomised trial.
Topics: Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Arthritis; Aspirin; Cardiovascular | 2017 |
Cardiovascular Safety of Celecoxib, Naproxen, or Ibuprofen for Arthritis.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Arthritis; Cardiovascular Diseases; Celecoxib; Cycloo | 2016 |
Cardiovascular Safety of Celecoxib, Naproxen, or Ibuprofen for Arthritis.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Arthritis; Cardiovascular Diseases; Celecoxib; Cycloo | 2016 |
Cardiovascular Safety of Celecoxib, Naproxen, or Ibuprofen for Arthritis.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Arthritis; Cardiovascular Diseases; Celecoxib; Cycloo | 2016 |
Cardiovascular Safety of Celecoxib, Naproxen, or Ibuprofen for Arthritis.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Arthritis; Cardiovascular Diseases; Celecoxib; Cycloo | 2016 |
Cardiovascular Safety of Celecoxib, Naproxen, or Ibuprofen for Arthritis.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Arthritis; Cardiovascular Diseases; Celecoxib; Cycloo | 2016 |
Cardiovascular Safety of Celecoxib, Naproxen, or Ibuprofen for Arthritis.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Arthritis; Cardiovascular Diseases; Celecoxib; Cycloo | 2016 |
Cardiovascular Safety of Celecoxib, Naproxen, or Ibuprofen for Arthritis.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Arthritis; Cardiovascular Diseases; Celecoxib; Cycloo | 2016 |
Cardiovascular Safety of Celecoxib, Naproxen, or Ibuprofen for Arthritis.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Arthritis; Cardiovascular Diseases; Celecoxib; Cycloo | 2016 |
Cardiovascular Safety of Celecoxib, Naproxen, or Ibuprofen for Arthritis.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Arthritis; Cardiovascular Diseases; Celecoxib; Cycloo | 2016 |
Rationale, design, and governance of Prospective Randomized Evaluation of Celecoxib Integrated Safety versus Ibuprofen Or Naproxen (PRECISION), a cardiovascular end point trial of nonsteroidal antiinflammatory agents in patients with arthritis.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis; Cardiovascular Diseases; Celecoxib; Cyclooxygena | 2009 |
Efficacy and safety of celecoxib versus diclofenac and omeprazole in elderly arthritis patients: a subgroup analysis of the CONDOR trial.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Arthritis; Celecoxib; Cyclooxygenase 2 Inhibitors; Di | 2012 |
Celecoxib versus diclofenac and omeprazole in reducing the risk of recurrent ulcer bleeding in patients with arthritis.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Agents; Arthritis; Celecoxib; Cyclooxygenase 2; | 2002 |
Celecoxib versus diclofenac plus omeprazole in high-risk arthritis patients: results of a randomized double-blind trial.
Topics: Adult; Aged; Arthritis; Celecoxib; Diclofenac; Double-Blind Method; Drug Therapy, Combination; Dyspe | 2004 |
The renal effects of the addition of low-dose aspirin to COX-2 selective and nonselective antiinflammatory drugs.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis; Aspirin; Blood Pressure; Celecoxib; Clinical Che | 2006 |
Safety of celecoxib in patients with ulcerative colitis in remission: a randomized, placebo-controlled, pilot study.
Topics: Adolescent; Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Arthritis; Celecoxib; Colitis, Ulc | 2006 |
Reduced incidence of gastroduodenal ulcers with celecoxib, a novel cyclooxygenase-2 inhibitor, compared to naproxen in patients with arthritis.
Topics: Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Arthritis; Celecoxib; Cyclo | 2001 |
69 other studies available for celecoxib and Arthritis
| Article | Year |
|---|---|
Novel antiarthritic agents with 1,2-isothiazolidine-1,1-dioxide (gamma-sultam) skeleton: cytokine suppressive dual inhibitors of cyclooxygenase-2 and 5-lipoxygenase.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Arthritis; Arthritis, Experimental; Blood Platelet | 2000 |
Synthesis and pharmacological evaluation of pyrazine N-acylhydrazone derivatives designed as novel analgesic and anti-inflammatory drug candidates.
Topics: Analgesics; Animals; Anti-Inflammatory Agents; Arthritis; Ear; Edema; Female; Freund's Adjuvant; Hyd | 2010 |
Arthritis and enthesitis during dupilumab therapy completely remitted by celecoxib.
Topics: Antibodies, Monoclonal, Humanized; Arthritis; Arthritis, Psoriatic; Celecoxib; Enthesopathy; Humans | 2021 |
Cardiovascular Safety of Celecoxib, Naproxen, or Ibuprofen for Arthritis.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis; Celecoxib; Humans; Ibuprofen; Naproxen; Pyrazole | 2017 |
Cardiovascular Safety of Celecoxib, Naproxen, or Ibuprofen for Arthritis.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis; Celecoxib; Humans; Ibuprofen; Naproxen; Pyrazole | 2017 |
Therapy: Celecoxib reduces risk of ulcer bleeding.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis; Celecoxib; Double-Blind Method; Gastrointestinal | 2017 |
Grip strength in mice with joint inflammation: A rheumatology function test sensitive to pain and analgesia.
Topics: Acetaminophen; Analgesics; Animals; Arthritis; Celecoxib; Disease Models, Animal; Diterpenes; Female | 2017 |
In high-risk patients with arthritis and previous upper GI bleeding, celecoxib vs naproxen reduced recurrent bleeding.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis; Celecoxib; Cyclooxygenase 2 Inhibitors; Humans; | 2017 |
Safety of non-steroidal anti-inflammatory drugs.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis; Blood Pressure; Blood Pressure Monitoring, Ambul | 2017 |
Editorial: gastrointestinal safety of COX-2 selective and nonselective NSAIDs-the impact of the PRECISION trial.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis; Celecoxib; Cyclooxygenase 2; Cyclooxygenase 2 In | 2018 |
Editorial: gastrointestinal safety of COX-2 selective and nonselective NSAIDs-the impact of the PRECISION trial. Authors' reply.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis; Celecoxib; Cyclooxygenase 2; Cyclooxygenase 2 In | 2018 |
Effects of aggregation of drug and diagnostic codes on the performance of the high-dimensional propensity score algorithm: an empirical example.
Topics: Adolescent; Adult; Aged; Algorithms; Arthritis; Celecoxib; Confounding Factors, Epidemiologic; Cyclo | 2013 |
Celecoxib-induced change in atrial electrophysiologic substrate in arthritis patients.
Topics: Analysis of Variance; Arthritis; Atrial Fibrillation; Celecoxib; Cohort Studies; Cyclooxygenase 2 In | 2014 |
Cyclooxygenase-2 inhibitor celecoxib attenuates joint contracture following immobilization in rat knees.
Topics: Administration, Oral; Animals; Arthritis; Celecoxib; Contracture; Cyclooxygenase 2; Cyclooxygenase 2 | 2016 |
Inflammation: NSAIDs and cardiovascular risk in arthritis.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis; Cardiovascular Diseases; Celecoxib; Humans; Ibup | 2017 |
Drug Rash with Eosinophilia and Systemic Symptoms (DRESS) syndrome induced by celecoxib and anti-tuberculosis drugs.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Antitubercular Agents; Arthritis; Celecoxib; Drug Er | 2008 |
Induction of multidrug resistance proteins in lymphocytes from patients with arthritic disorders.
Topics: Arthritis; ATP Binding Cassette Transporter, Subfamily B; Celecoxib; Cyclooxygenase Inhibitors; Huma | 2008 |
Determination of two COX-2 inhibitors in serum and synovial fluid of patients with inflammatory arthritis by ultra performance liquid chromatography-inductively coupled plasma mass spectroscopy and quadrupole time-of-flight mass spectrometry.
Topics: Adult; Aged; Arthritis; Celecoxib; Chromatography, High Pressure Liquid; Cyclooxygenase 2 Inhibitors | 2009 |
Therapeutic effect of Aralia cordata extracts on cartilage protection in collagenase-induced inflammatory arthritis rabbit model.
Topics: Animals; Anti-Inflammatory Agents; Apoptosis; Aralia; Arthritis; Cartilage; Caspase 3; Celecoxib; Ch | 2009 |
Breast-cancer-associated metastasis is significantly increased in a model of autoimmune arthritis.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Antibodies, Monoclonal; Arthritis; Autoimmune Dise | 2009 |
Drug-induced hypersensitivity syndrome followed by persistent arthritis.
Topics: Anti-Arrhythmia Agents; Arthralgia; Arthritis; Celecoxib; Chronic Disease; Cyclooxygenase 2 Inhibito | 2012 |
Gastrointestinal-sparing effects of novel NSAIDs in rats with compromised mucosal defence.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Arthritis; Aspirin; Celecoxib; Drug Therapy, Combi | 2012 |
Nephrotic syndrome and interstitial nephritis associated with celecoxib.
Topics: Acute Disease; Anti-Inflammatory Agents, Non-Steroidal; Arthritis; Celecoxib; Cyclooxygenase 2; Cycl | 2002 |
[Financial interests characterize published reports on coxiber. Whom can we rely on?].
Topics: Anti-Inflammatory Agents, Non-Steroidal; Antirheumatic Agents; Arthritis; Arthritis, Rheumatoid; Cel | 2002 |
NSAIDs, Helicobacter pylori, and Pandora's Box.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Agents; Arthritis; Celecoxib; Cyclooxygenase 2; | 2002 |
[Gastrointestinal complications caused by NSAIDs. Over 60% of arthrosis patients are endangered].
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Arthritis; Celecoxib; Clinical Trials as Topic; Cyclo | 2003 |
Celecoxib-induced fixed drug eruption.
Topics: Administration, Topical; Anti-Inflammatory Agents; Anti-Inflammatory Agents, Non-Steroidal; Arthriti | 2003 |
Cardiovascular thrombotic events in arthritis trials of the cyclooxygenase-2 inhibitor celecoxib.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis; Celecoxib; Cyclooxygenase Inhibitors; Humans; Py | 2003 |
Lessons from early large-scale adoption of celecoxib and rofecoxib by Australian general practitioners.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Arthritis; Aust | 2003 |
Persistence with COX-2 inhibitors in managed care: an analysis of claims data.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis; Celecoxib; Cyclooxygenase 2; Cyclooxygenase 2 In | 2003 |
Why don't we initiate more large simple randomized controlled trials?
Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis; Canada; Celecoxib; Consumer Product Safety; Cycl | 2003 |
[Homeopathy suppresses COX- and LOX activity. Soft therapy for arthrosis ills].
Topics: Arthritis; Celecoxib; Cyclooxygenase Inhibitors; Double-Blind Method; Formularies, Homeopathic as To | 2004 |
Pulmonary edema and possible pneumonitis associated with celecoxib.
Topics: Arthritis; Celecoxib; Cyclooxygenase 2; Female; Humans; Isoenzymes; Membrane Proteins; Middle Aged; | 2004 |
COX-2-specific inhibitor or proton pump inhibitor plus traditional NSAID: is either approach sufficient for patients at highest risk of NSAID-induced ulcers?
Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis; Aspirin; Celecoxib; Cyclooxygenase 2; Cyclooxyge | 2004 |
Vioxx withdrawal alarms cancer prevention researchers.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Anticarcinogenic Agents; Arthritis; Celecoxib; Cyc | 2004 |
Arthritis medicines and cardiovascular events--"house of coxibs".
Topics: Adenoma; Anti-Inflammatory Agents, Non-Steroidal; Arthritis; Cardiovascular Diseases; Celecoxib; Cyc | 2005 |
Multiple comparisons in drug efficacy studies: scientific or marketing principles?
Topics: Adult; Arthritis; Attention Deficit Disorder with Hyperactivity; Celecoxib; Child; Clinical Trials a | 2004 |
Raising the safety bar--the FDA's coxib meeting.
Topics: Advertising; Advisory Committees; Anti-Inflammatory Agents, Non-Steroidal; Arthritis; Cardiovascular | 2005 |
Assessing the cost-effectiveness of COX-2 specific inhibitors for arthritis in the Veterans Health Administration.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Arthritis; Celecoxib; Cost-Benefit Analysis; Cyclooxy | 2005 |
Celecoxib-induced nephrotoxicity in a renal transplant recipient.
Topics: Arthritis; Celecoxib; Cyclooxygenase Inhibitors; Humans; Kidney Diseases; Kidney Transplantation; Ma | 2005 |
Tailoring arthritis therapy in the wake of the NSAID crisis.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis; Celecoxib; Cyclooxygenase Inhibitors; Humans; La | 2005 |
Coxibs and cardiovascular risk.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis; Aspirin; Cardiovascular Diseases; Celecoxib; Cli | 2005 |
Quantitative assessment of the gastrointestinal and cardiovascular risk-benefit of celecoxib compared to individual NSAIDs at the population level.
Topics: Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Arthritis; Cardiovascular D | 2007 |
Nitric oxide deficiency promotes vascular side effects of cyclooxygenase inhibitors.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Aorta; Arthritis; Biological Availability; Blood P | 2006 |
Selective COX-2 inhibitors and risk of thromboembolic events - regulatory aspects.
Topics: Adverse Drug Reaction Reporting Systems; Animals; Arthritis; Celecoxib; Cyclooxygenase 2 Inhibitors; | 2006 |
Coxibs: can this class of drugs survive?
Topics: Arthritis; Cardiovascular Diseases; Celecoxib; Cyclooxygenase 2 Inhibitors; Etoricoxib; Evidence-Bas | 2005 |
Collagen-induced arthritis as a model of hyperalgesia: functional and cellular analysis of the analgesic actions of tumor necrosis factor blockade.
Topics: Animals; Arthritis; Astrocytes; Behavior, Animal; Celecoxib; Collagen; Cyclooxygenase Inhibitors; Di | 2007 |
Response to Ray and colleagues: the called-for large clinical trial is already ongoing.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Agents; Arthritis; Celecoxib; Diclofenac; Humans | 2008 |
Safer arthritis drugs on the horizon.
Topics: Arthritis; Celecoxib; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Huma | 1998 |
Cancer and arthritis share underlying processes.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Anticarcinogenic Agents; Arthritis; Celecoxib; Cell Transfo | 1998 |
Decisions loom on selective COX-2 inhibitors.
Topics: Arthralgia; Arthritis; Celecoxib; Clinical Trials as Topic; Cyclooxygenase Inhibitors; Humans; Lacto | 1999 |
From the Food and Drug Administration.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Anticonvulsants; Arthritis; Celecoxib; Communicable Disease | 1999 |
The management of pain and inflammation in orthopedic medicine: question-and-answer period.
Topics: Arthritis; Celecoxib; Clinical Trials as Topic; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclo | 1999 |
Outfoxing pathways of pain. 'COX-2' drugs are easier on stomach.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis; Celecoxib; Cyclooxygenase Inhibitors; Drug Appro | 1998 |
What did you say? I can't quite understand your spoken order.
Topics: Antidepressive Agents, Second-Generation; Arthritis; Celecoxib; Citalopram; Cyclooxygenase Inhibitor | 1999 |
New versus old drugs for arthritis.
Topics: Arthritis; Celecoxib; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Huma | 1999 |
Arthritis drug approved for polyp prevention blazes trail for other prevention trials.
Topics: Adenomatous Polyposis Coli; Anti-Inflammatory Agents, Non-Steroidal; Anticarcinogenic Agents; Arthri | 2000 |
Celecoxib (Celebrex): 1 year later.
Topics: Adult; Adverse Drug Reaction Reporting Systems; Aged; Anti-Inflammatory Agents, Non-Steroidal; Arthr | 2000 |
COX-2 inhibitors and Celebrex: safe or suspect?
Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis; Celecoxib; Cyclooxygenase 2; Cyclooxygenase 2 In | 1999 |
Cyclooxygenase-2 inhibitor celecoxib: a possible cause of gastropathy and hypoprothrombinemia.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Anticoagulants; Arthritis; Atrial Fibrillation; Bicar | 2000 |
Visual disturbance associated with celecoxib.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Arthritis; Celecoxib; Cyclooxygenase 2; Cyclooxygenas | 2001 |
Economic evaluation of celecoxib, a new cyclo-oxygenase 2 specific inhibitor, in Switzerland.
Topics: Anemia; Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Agents; Arthritis; Celecoxib; Clinical T | 2001 |
Pain relief at a price. A blow to the heart?
Topics: Arthritis; Cardiovascular Diseases; Celecoxib; Clinical Trials as Topic; Cyclooxygenase Inhibitors; | 2001 |
[Renal tolerance of selective inhibitors of cyclooxygenase type 2].
Topics: Acute Kidney Injury; Adult; Aged; Aged, 80 and over; Animals; Anti-Inflammatory Agents, Non-Steroida | 2001 |
[Cox-2 inhibitors in the focus. Rofecoxib as effective as the "classics"].
Topics: Acetaminophen; Analgesics, Non-Narcotic; Analgesics, Opioid; Anti-Inflammatory Agents, Non-Steroidal | 2001 |
[Side effects cause enormous costs. Expensive arthritis therapy].
Topics: Analgesics, Non-Narcotic; Anti-Inflammatory Agents, Non-Steroidal; Arthritis; Butanones; Celecoxib; | 2001 |
Nonsteroidal anti-inflammatory drugs, coxibs, and cardio-renal physiology: a mechanism-based approach.
Topics: Adenomatous Polyposis Coli; Anti-Inflammatory Agents, Non-Steroidal; Arthritis; Cardiovascular Syste | 2002 |
Are selective COX 2 inhibitors superior to traditional non steroidal anti-inflammatory drugs?
Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis; Arthritis, Rheumatoid; Celecoxib; Cyclooxygenase | 2002 |
[Hyperkalemia and celecoxib].
Topics: Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Arthritis; Celecoxib; Cyclooxygena | 2002 |